Genomic Diagnostics

Site

GD Vic – Healius Pathology Pty Ltd

Accreditation No.

19619

Site No.

22717

Date of Accreditation

17 Dec 2014

Address

460 Lower Heidelberg Road
Heidelberg, VIC 3084
Australia

sdspathology.com.au

Contact

Ms Amanda Portelli P: +61 (03) 99182028

Availability

Services available to external clients

Supervision

GX (General)

Genomic Diagnostics address map

Scope of Accreditation

Print scopes
GD Vic – Healius Pathology Pty Ltd

ISO 15189 (2022)

  • This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.

Human Pathology

Medicare expiry date

02 Mar 2027

Last Activity Date

19 Jul 2024

Service Product Determinant
Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes Blood Cystic fibrosis; Fragile X
Fragile X; Gilberts disease
Factor V Leiden; HLA-B27; Haemochromatosis; Methylenetetrahydrofolate reductase (MTHFR); Prothrombin variant; Thrombophilia
Coeliac disease
Thiopurine methyltransferase (TPMT); α1-Antitrypsin
α-Thalassaemia
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes Blood Quantitative calculation of p190 positive BCR::ABL1
Immunoglobulin (Ig); Quantitative calculation of p210 positive BCR::ABL1 transcripts
Qualitative calculation of p190 positive BCR::ABL1 transcripts; Quantitative calculation of p190 positive BCR::ABL1
Myeloproliferative disorders
Blood; Bone marrow Blood borne tumours; JAK2 exon 12 mutation
Formalin-fixed paraffin-embedded (FFPE) tissues BRAF mutation analysis; EGFR mutation analysis; KRAS mutation analysis; NRAS mutation analysis; Solid tumours
KIT mutation analysis; Non-small cell lung cancer and other tumours; Solid tumours
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes Formalin-fixed paraffin-embedded (FFPE) tissues BRCA1 somatic mutation testing – ovarian cancer; BRCA2 somatic mutation testing – prostate cancer
Solid tumours
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Whole genome sequencing for non-inherited (somatic) DNA/RNA changes Blood; Bone marrow Blood borne tumours
Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted genes Blood Spinal muscular atrophy
Breast cancer; Hereditary colorectal cancer; Inherited disorders; Ovarian cancer; Spinal muscular atrophy
Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted genes Blood Spinal muscular atrophy
Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted panels for inherited (germline) DNA/RNA changes Blood Cystic fibrosis; Familial hypercholesterolemia
Hereditary breast and ovarian cancer syndrome
Breast cancer; Cystic fibrosis; Hereditary colorectal cancer; Inherited disorders; Ovarian cancer
Breast cancer; Hereditary colorectal cancer; Inherited disorders
Breast cancer; Cystic fibrosis; Hereditary colorectal cancer; Inherited disorders; Ovarian cancer
Molecular genetics - Non-invasive prenatal (genetic) screening Maternal blood Aneuploidy for chromosomes X and Y; Rare autosome aneuploidy and segmental genomic imbalances; Trisomy 13, trisomy 18, trisomy 21
Molecular genetics - Predictive genetic testing - Targeted genes Blood Breast cancer; Hereditary colorectal cancer; Inherited disorders
Breast cancer; Hereditary colorectal cancer; Inherited disorders
Molecular genetics/Cytogenetics - Bioinformatic analysis DNA sequences Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation
Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation

The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.

Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.